Expert Details

Stroke, Preclinical Drug Development, Translational Research

ID: 722846 California, USA

Expert A. Expert, PhD. FAHA is the Director of Translational Research at Employer in Los Angeles, California. He is directing the preclinical development of new methods to treat acute ischemic stroke. Expert has expertise in developing small molecules, proteins and novel devices to embolic stroke and hemorrhagic stroke. He also has extensive expertise in using animal models to develop new therapeutics (drugs) and devices (ultrasound/lasers). Expert's research focuses on novel multifunctional antioxidants including spin trap agents (NXY-059, STAZN), NMDA antagonists (memantine), thrombolytics (tPA, TNK-tPA, microplasmin) and novel neuroprotective compounds such as CEPO. He is also developing drug combinations to increase the safety profile and efficacy of the thrombolytics tPA and TNK. Expert has consulted for many pharmaceutical and biotechnology companies.

Array

He consults for Medicorp: drug development for CNS diseases including stroke.He consults for the Gerson Lehrman Group: drug development for CNS diseases including stroke.He consults for the pharmaceutical and biotechnology industry and acts as a CRO to determine the potential of new drugs and devices.He consults for HCRC Corporation
: drug development for CNS diseases including stroke.He consults for Expert i-pinions: drug development for CNS diseases including stroke

Request Expert

Education

Year	Degree	Subject	Institution
Year: 1988	Degree: PhD	Subject: Pharmacology- Neuroscience	Institution: McGill University

Work History

Years	Employer	Title	Department
Years: 2009 to Present	Employer: Undisclosed	Title: Director of Translational Research	Department: Neurology
Responsibilities: Translational development of new therapies for acute ischemic stroke, hemorrhagic stroke and traumatic brain injury.
Years	Employer	Title	Department
Years: 1998 to 2005	Employer: UCSD	Title: Research Scientist, Faculty PI	Department: Neuroscience
Responsibilities: Prelcinical development of new drugs and devices to treat acute ischemic stroke including Cerovivie (NXY-059), MMP inhibitors, TACE inhibitors, novel NMDA antagonists, new thrombolytics. Devices: Lasers and Ultrasound

Government Experience

Years	Agency	Role	Description
Years: 2009 to 2005	Agency: VASDHS	Role: Research Scientist	Description: Preclinical drug development for stroke

Career Accomplishments

Associations / Societies
SFN, AHA Stroke Council

Professional Appointments
ad hoc reviewer Stroke, Brain Research, Neurology, Exp. Neurol.

Awards / Recognition
FAHA

Publications and Patents Summary
He has 240 publications including approximately 95 peer-reviewed papers and numerous reviews. He also has 130 abstracts for presentations at scientific meetings.

Fields of Expertise

nervous system disease, central nervous system disease, cerebral hemorrhage, brain ischemia, leukodystrophy, brain tissue, drug development, neurodegenerative disease, neuropharmacology, neuroscience, pharmacology, intracranial hemorrhage, brain disease, nervous system, neurology, cardiovascular system, cardiovascular drug therapy